Lexington, MA, United States
Lexington, MA, United States
SEARCH FILTERS
Time filter
Source Type

The present invention is directed toward respirable dry particles for delivery of divalent metal cation salts and/or monovalent cation salts to the respiratory tract and methods for treating a subject having a respiratory disease and/or infection.


Patent
Pulmatrix | Date: 2016-09-27

The present invention is directed toward respirable dry powders and particles for systemic delivery of pharmaceutically active agents or delivery to the respiratory tract. The dry powders contain one or more monovalent metal cations (such as Na^(+)), are small and dispersible.


A dry powder containing dry particles that contain a tiotropium salt, one or more amino acids, and acid content, and optionally, sodium chloride, and/or one or more additional therapeutic agents, wherein the molar ratio of acid to amino acid is from about 0.0005 to about 5, or 0.002 to about 1. In one aspect, the dry powder containing dry particles is suitable for administration to the respiratory tract. In one aspect, the dry powder containing dry particles is a respirable dry powder contains respirable dry particles that contain a tiotropium salt, one or more amino acids, acid content, sodium chloride, and optionally one or more additional therapeutic agents, wherein the tiotropium salt is about 0.01% to about 0.5%, the leucine is about 5% to about 40%, the sodium chloride is about 50% to about 90%, the optional one or more additional therapeutic agents are up to about 30%, and the molar ratio of acid to amino acid is from about 0.002 to about 1, where all percentages are weight percentages on a dry basis and all the components of the respirable dry particles amount to 100%.


The invention relates to, for example, a respirable dry powder that contains respirable dry particles that contains a tiotropium salt, one or more amino acids, sodium chloride, and optionally one or more additional therapeutic agents, where the tiotropium salt is about 0.01% to about 0.5%, the one or more amino acids is about 5% to about 40%, the sodium chloride is about 50% to about 90%, and the optional one or more additional therapeutic agents are up to about 30%, where all percentages are weight percentages on a dry basis and all the components of the respirable dry particles amount to 100%, and wherein the majority of the one or more amino acids are present in a crystalline state.


The present invention is directed toward respirable dry particles for delivery of divalent metal cation salts and/or monovalent cation salts to the respiratory tract and methods for treating a subject having a respiratory disease and/or infection.


The present invention relates to respirable dry powders that contain respirable dry particles that comprise calcium lactate, sodium chloride, leucine, and one or more additional therapeutic agents; wherein the ratio of calcium cation to sodium cation is about 4:1 (mole:mole); and, wherein the calcium lactate is about 45.0% (w/w) to about 58.6% (w/w), and the sodium chloride is about 1.9% (w/w) to about 3.9% (w/w), where all weights are on a dry basis.


Patent
Pulmatrix | Date: 2015-03-24

The present invention is directed toward respirable dry powders and particles for systemic delivery of pharmaceutically active agents or delivery to the respiratory tract. The dry powders contain one or more monovalent metal cations (such as Na^(+)), are small and dispersible.


Patent
Pulmatrix | Date: 2016-07-27

The invention relates to respirable dry particles that contain one or more divalent metal cations, such as magnesium, in an amount of less than 3% by weight, and to dry powders that contain the respirable particles. The dry particles can further contain an active agent, or can be used as carrier particles to deliver an active agent.


The present invention is directed toward respirable dry particles for delivery of divalent metal cation salts and/or monovalent cation salts to the respiratory tract and methods for treating a subject having a respiratory disease and/or infection.


Patent
Pulmatrix | Date: 2015-09-30

The present invention relates to respirable dry powder comprising respirable dry particles that comprise sodium chloride, leucine, and tiotropium bromide, wherein the sodium chloride is about 60% to about 90%, the leucine is about 10% to about 40%, the tiotropium bromide is about 0.01% to about 0.5%, and optionally one or more additional therapeutic agents up to about 20%, wherein all percentages are weight percentages on a dry basis and all the components of the respirable dry particles amount to 100%. The invention also relates to respirable dry powders that contain respirable dry particles that comprise sodium chloride, leucine, and tiotropium bromide, wherein the sodium chloride is 67% to 84%, the leucine is 12% to 28%, the tiotropium bromide is about 0.01% to about 0.5%, and optionally one or more additional therapeutic agents up to about 20%, wherein all percentages are weight percentages on a dry basis and all the components of the respirable dry particles amount to 100%. The invention also relates to respirable dry powders that contain respirable dry particles that comprise about 79.5% to about 80.5% (w/w) sodium chloride, about 19.5% to about 20.5% (w/w) leucine, and about 0.01% to about 0.5% (w/w) tiotropium bromide, and methods for treating a subject using the respirable dry powders.

Loading Pulmatrix collaborators
Loading Pulmatrix collaborators